Cytek Biosciences, Inc. 8-K

What Happened
Cytek Biosciences, Inc. (CTKB) filed an 8-K reporting the results of its 2026 annual meeting held June 10, 2026. Of 129,142,587 shares outstanding as of the April 13, 2026 record date, 111,161,490 shares (about 86.1%) were represented at the virtual meeting. Three Class II director nominees — Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D. — were elected to serve until the 2029 annual meeting. The advisory vote on executive compensation was approved, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2026.

Key Details

• Shares outstanding (record date Apr 13, 2026): 129,142,587; shares represented at meeting: 111,161,490 (~86.1%).
• Director election results:
  • Vera Imper, Ph.D.: 64,769,976 votes for; 20,723,477 withheld; 25,668,037 broker non-votes.
  • Glenn P. Muir: 79,599,103 for; 5,894,350 withheld; 25,668,037 broker non-votes.
  • Ming Yan, Ph.D.: 76,741,063 for; 8,752,390 withheld; 25,668,037 broker non-votes.
• Advisory (non-binding) vote on 2025 executive compensation: 84,794,380 for; 677,861 against; 21,212 abstentions; 25,668,037 broker non-votes.
• Ratification of auditor (Deloitte & Touche LLP) for 2026: 110,533,253 for; 479,883 against; 148,354 abstentions.

Why It Matters
The election results confirm board continuity through 2029, which can influence strategic and governance direction. The advisory approval of executive pay signals shareholder support for compensation policies (though non-binding). Ratifying Deloitte as auditor finalizes the company’s independent accounting oversight for 2026. Investors should note the sizable number of broker non-votes on director and advisory items (25,668,037), which occur when brokers cannot vote discretionary shares and can affect vote totals on non-routine matters.